Article Text

Download PDFPDF
Images in Thorax
Contralateral recurrence of inflammatory myofibroblastic tumour of the lung 10 years after pneumonectomy
  1. Daniel C Vis1,
  2. Margaret M Kelly2,
  3. Andrew G Lee3,
  4. Gary Gelfand4,
  5. Kerri A Johannson1,5
  1. 1 Department of Medicine, University of Calgary, Calgary, Alberta, Canada
  2. 2 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
  3. 3 Department of Radiology, University of Calgary, Calgary, Alberta, Canada
  4. 4 Department of Surgery, University of Calgary, Calgary, Alberta, Canada
  5. 5 Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
  1. Correspondence to Dr Kerri A Johannson, Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada; kerri.johannson{at}

Statistics from


Inflammatory myofibroblastic tumour (IMT) is a rare form of inflammatory pseudotumour of the lung. Complete surgical resection is the treatment of choice, with corticosteroid-based medical therapy reserved for cases where complete resection is not possible.1 To date, the majority of recurrent cases have occurred subsequent to incomplete resection or after discontinuation of steroids when used as primary therapy.1 2 There is a paucity of data guiding the follow-up of patients who undergo complete resection. In addition, the efficacy of oral steroids in the treatment of IMT remains poorly characterised and the optimal duration of therapy is unknown.

Case presentation

A 46-year-old lifetime non-smoker presented in December 2015 with dyspnoea, fatigue, night sweats and weight loss. A chest X-ray demonstrated a new left lower lobe mass. His history was significant only for a right pneumonectomy in June 2005 for a large inflammatory pseudotumour. This pneumonectomy was performed for definitive surgical management, as the mass was adjacent to …

View Full Text


  • Contributors DCV and KAJ conceived the project. DCV, MMK, AGL, GG and KAJ contributed important intellectual content. All authors contributed to and approved the final version of the manuscript. KAJ is the guarantor of this manuscript, taking full responsibility for its contents.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Author note 1089

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.